BioCentury
ARTICLE | Financial News

Taiwan Liposome raises $25.1M in IPO

December 27, 2012 1:49 AM UTC

Drug delivery company Taiwan Liposome Co. Inc. (GreTai:4152) raised NT$730.3 million ($25.1 million) through the sale of 4.6 million shares at NT$158 in an IPO on the GreTai Securities Market. The company is formulating generics and new chemical entities with its lipid-based delivery technologies. Taiwan Liposome markets ProFlow, an emulsion formulation of the prostaglandin E1 (PGE1) alprostadil, in Taiwan to treat peripheral arterial disease (PAD), as well as diabetic neuropathy and ulcers. The company's Lipotecan is in Phase II testing for cancer. The polymeric micelle formulation of a multi-functional camptothecin derivative has Orphan Drug designation in the U.S and EU for hepatocellular carcinoma (HCC). ...